For instance, in ZDF rats, empagliflozin, a SGLT2 inhibitor lowering glucose levels and the resulting glycotoxicity (oxidative stress, AGEs/RAGE signaling (advanced glycation end-products and their receptor)), prevents the development of endothelial dysfunction, despite persisting hyperlipidemia and hyperinsulinemia [36]. This evidence concerns the gene SLC5A2 and endothelial dysfunction.